EC Says ‘Bolar Exemption’ Should Cover Pricing, Reimbursement & HTA Processes

Pricing and reimbursement processes as well as health technology assessments should be explicitly included in the procedures that can be conducted for generic and biosimilar products without infringing patent rights, according to the European Commission’s legislative revision proposals.